Steven P. Luckman

5.2k total citations · 5 hit papers
16 papers, 4.3k citations indexed

About

Steven P. Luckman is a scholar working on Oncology, Molecular Biology and Neurology. According to data from OpenAlex, Steven P. Luckman has authored 16 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Neurology. Recurrent topics in Steven P. Luckman's work include Bone health and treatments (8 papers), Myasthenia Gravis and Thymoma (6 papers) and Antifungal resistance and susceptibility (5 papers). Steven P. Luckman is often cited by papers focused on Bone health and treatments (8 papers), Myasthenia Gravis and Thymoma (6 papers) and Antifungal resistance and susceptibility (5 papers). Steven P. Luckman collaborates with scholars based in United Kingdom, Norway and Netherlands. Steven P. Luckman's co-authors include Michael J. Rogers, Fraser P. Coxon, R.G.G. Russell, Helena L. Benford, Julie C. Frith, Jukka Mönkkönen, D. E. Hughes, Sharon Gordon, Frank H. Ebetino and Keith Thompson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Steven P. Luckman

16 papers receiving 4.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nitrogen-Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post-Translational Prenylation of GTP-Binding Proteins, Including Ras

1998 977 citations Steven P. Luckman, D. E. Hughes et al. Journal of Bone and Mineral Research profile →
Structure-Activity Relationships for Inhibition of Farnesyl Diphosphate Synthase in Vitro and Inhibition of Bone Resorption in Vivo by Nitrogen-Containing Bisphosphonates

2001 726 citations James E. Dunford, Keith Thompson et al. Journal of Pharmacology and Experimental Therapeutics profile →
Cellular and molecular mechanisms of action of bisphosphonates

2000 720 citations Michael J. Rogers, Sharon Gordon et al. Cancer profile →
Cellular and molecular mechanisms of action of bisphosphonates

2000 571 citations Michael J. Rogers, Sharon Gordon et al. Cancer profile →
Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro

1999 570 citations John Fisher, Michael J. Rogers et al. Proceedings of the National Academy of Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Steven P. Luckman United Kingdom	12	3.4k	1.8k	1.4k	920	502	16	4.3k
Julie C. Frith United Kingdom	13	2.3k 0.7×	1.1k 0.6×	928 0.6×	659 0.7×	358 0.7×	17	2.9k
Jonathan R. Green Switzerland	22	2.4k 0.7×	1.1k 0.6×	930 0.6×	791 0.9×	526 1.0×	41	3.2k
Helena L. Benford United Kingdom	8	1.8k 0.5×	868 0.5×	660 0.5×	526 0.6×	314 0.6×	9	2.2k
Frieder Bauss Germany	32	1.9k 0.6×	1.5k 0.8×	850 0.6×	467 0.5×	241 0.5×	81	2.9k
Katri S. Selander Finland	34	1.9k 0.6×	295 0.2×	1.5k 1.0×	388 0.4×	502 1.0×	63	3.5k
Aristotle Bamias Greece	28	1.9k 0.6×	858 0.5×	785 0.5×	189 0.2×	792 1.6×	88	3.3k
David Roodman United States	13	1.4k 0.4×	569 0.3×	1.0k 0.7×	278 0.3×	162 0.3×	33	2.3k
R. Graham United Kingdom	15	913 0.3×	458 0.3×	454 0.3×	237 0.3×	263 0.5×	30	1.8k
Casey Capparelli United States	10	2.3k 0.7×	885 0.5×	3.0k 2.1×	138 0.1×	97 0.2×	10	3.9k
Aina He China	32	891 0.3×	158 0.1×	900 0.6×	117 0.1×	749 1.5×	83	2.8k

Countries citing papers authored by Steven P. Luckman

Since Specialization

Citations

This map shows the geographic impact of Steven P. Luckman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven P. Luckman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven P. Luckman more than expected).

Fields of papers citing papers by Steven P. Luckman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven P. Luckman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven P. Luckman. The network helps show where Steven P. Luckman may publish in the future.

Co-authorship network of co-authors of Steven P. Luckman

This figure shows the co-authorship network connecting the top 25 collaborators of Steven P. Luckman. A scholar is included among the top collaborators of Steven P. Luckman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven P. Luckman. Steven P. Luckman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Petzold, Axel, et al.. (2011). Matrix Metalloproteinases in Myasthenia Gravis. European Neurology. 65(1). 53–58. 16 indexed citations

Luckman, Steven P., Nils Erik Gilhus, & Fredrik Romi. (2011). Matrix Metalloproteinase-3 in Myasthenia Gravis Compared to Other Neurological Disorders and Healthy Controls. SHILAP Revista de lepidopterología. 2011. 1–4. 15 indexed citations

Romi, Fredrik, Nils Erik Gilhus, & Steven P. Luckman. (2008). Serum matrix metalloproteinase-3 levels are elevated in myasthenia gravis. Journal of Neuroimmunology. 195(1-2). 96–99. 10 indexed citations

Luckman, Steven P., et al.. (2008). Myasthenia gravis sera have no effect on cardiomyocytes in vitro. Journal of Neuroimmunology. 201-202. 74–79. 4 indexed citations

Luckman, Steven P., et al.. (2006). Effects of myasthenia gravis patient sera on human myoblast cultures. Acta Neurologica Scandinavica. 113(s183). 28–32. 1 indexed citations

Luckman, Steven P., et al.. (2005). Morphological effects of myasthenia gravis patient sera on human muscle cells. Muscle & Nerve. 33(1). 93–103. 8 indexed citations

Luckman, Steven P., D. E. Hughes, Fraser P. Coxon, R.G.G. Russell, & Michael J. Rogers. (2005). Nitrogen-Containing Biphosphonates Inhibit the Mevalonate Pathway and Prevent Post-Translational Prenylation of GTP-Binding Proteins, Including Ras. Journal of Bone and Mineral Research. 20(7). 1265–1274. 12 indexed citations

Luckman, Steven P., et al.. (2003). Partial characterization of cell-type X collagen interactions. Biochemical Journal. 372(2). 485–493. 34 indexed citations

Dunford, James E., Keith Thompson, Fraser P. Coxon, et al.. (2001). Structure-Activity Relationships for Inhibition of Farnesyl Diphosphate Synthase in Vitro and Inhibition of Bone Resorption in Vivo by Nitrogen-Containing Bisphosphonates. Journal of Pharmacology and Experimental Therapeutics. 296(2). 235–242. 726 indexed citations breakdown →

10.

Rogers, Michael J., Sharon Gordon, Helena L. Benford, et al.. (2000). Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 88(S12). 2961–2978. 720 indexed citations breakdown →

11.

Rogers, Michael J., Sharon Gordon, Helena L. Benford, et al.. (2000). Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 88(S12). 2961–2978. 571 indexed citations breakdown →

12.

Rogers, Michael J., Julie C. Frith, Steven P. Luckman, et al.. (1999). Molecular mechanisms of action of bisphosphonates. Bone. 24(5). 73S–79S. 181 indexed citations

13.

Fisher, John, Michael J. Rogers, Steven P. Luckman, et al.. (1999). Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proceedings of the National Academy of Sciences. 96(1). 133–138. 570 indexed citations breakdown →

14.

Russell, R.G.G., Michael J. Rogers, Julie C. Frith, et al.. (1999). The pharmacology of bisphosphonates and new insights into their mechanisms of action. Journal of Bone and Mineral Research. 14(S2). 53–65. 206 indexed citations

15.

Luckman, Steven P., Fraser P. Coxon, Frank H. Ebetino, R.G.G. Russell, & Michael J. Rogers. (1998). Heterocycle-Containing Bisphosphonates Cause Apoptosis and Inhibit Bone Resorption by Preventing Protein Prenylation: Evidence from Structure-Activity Relationships in J774 Macrophages. Journal of Bone and Mineral Research. 13(11). 1668–1678. 222 indexed citations

16.

Luckman, Steven P., D. E. Hughes, Fraser P. Coxon, R.G.G. Russell, & Michael J. Rogers. (1998). Nitrogen-Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post-Translational Prenylation of GTP-Binding Proteins, Including Ras. Journal of Bone and Mineral Research. 13(4). 581–589. 977 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact